Clinical Trials Logo

Clinical Trial Summary

Our project is going to enroll patients with stage IV NSCLC with EGFR mutation and evaluate whether primary tumor resection after receiving the afatinib can prolong survival. This project is supposed to establish a new treatment protocol for stage IV NSCLC with EGFR mutation.


Clinical Trial Description

In Taiwan, non-small cell lung cancer (NSCLC) has been the leading cause of cancer death, making a phenomenal impact on public health. By understanding the oncogenic driver mutations of NSCLC (e.g. EGFR mutation or ALK rearrangement), the target therapy has taken the place of chemotherapy for its effectiveness and specificity, becoming the new standard of care for stage IV NSCLC. Despite the progress of medical treatment, the majority of patients with stage IV NSCLC still underwent disease progression after a period of time. Noticeably, more than half of the progression was restricted to the original sites of the tumor. It brings up the hypothesis that a combination of local consolidative therapy (e.g. surgery or radial therapy) and medical treatment could be beneficial for these patients. This has been advocated by the latest clinical trials as well. Our project is going to enroll patients with stage IV NSCLC with EGFR mutation and evaluate whether primary tumor resection after receiving the afatinib can prolong the progression-free survival. This project is supposed to establish a new treatment protocol for stage IV NSCLC with EGFR mutation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05215548
Study type Interventional
Source National Taiwan University Hospital
Contact Jin-Shing Chen, M.D., Ph.D.
Phone 886-2-2322-0322
Email chenjs@ntu.edu.tw
Status Recruiting
Phase Phase 2
Start date September 27, 2021
Completion date July 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05543330 - A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC Phase 1/Phase 2
Recruiting NCT04106180 - SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC Phase 2
Recruiting NCT04042558 - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies Phase 2
Completed NCT04507217 - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC Phase 2
Recruiting NCT04467801 - Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy Phase 2
Active, not recruiting NCT04027647 - Phase 2 Study of Dacomitinib in NSCLC Phase 2
Recruiting NCT04768491 - Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Not yet recruiting NCT04492969 - Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
Recruiting NCT04116918 - Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
Terminated NCT03411473 - Study of AGEN1884 With Pembrolizumab in 1L NSCLC Phase 2
Recruiting NCT03564197 - 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC N/A
Not yet recruiting NCT06219317 - Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC Phase 2
Not yet recruiting NCT04604470 - Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
Recruiting NCT05132218 - Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Not yet recruiting NCT04136535 - Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC Phase 2
Completed NCT03184571 - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Phase 2
Completed NCT06339554 - Alectinib-induced Endocrine Toxicity
Active, not recruiting NCT04549428 - Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC Phase 2
Recruiting NCT03647956 - Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors Phase 2
Recruiting NCT04180501 - SRS Sequential Sindilimab in Brain Metastasis of NSLSC Phase 2